BHCM
ADAP

Boulder Hill Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Boulder Hill Capital Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-90,800
Closed -$143K – 3
2024
Q1 		$143K Buy
+90,800
New +$110K 0.06% 90

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Boulder Hill Capital Management's ADAP Position: Q2 2024 in Review

Boulder Hill Capital Management sold out of Adaptimmune Therapeutics (ADAP) in Q2 2024, closing a stake of 90,800 shares — an estimated $143K sold.

Boulder Hill Capital Management first reported a position in ADAP in Q1 2024 and held it in 1 quarter. The position peaked at $143K in Q1 2024. 76 funds tracked by Wall St. Rank hold ADAP as of Q2 2024.

  • Boulder Hill Capital Management reported no remaining Adaptimmune Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Boulder Hill Capital Management sold 90,800 Adaptimmune Therapeutics shares in Q2 2024, an estimated $143K.
  • Boulder Hill Capital Management first reported a position in Adaptimmune Therapeutics in Q1 2024 and held it in 1 quarter.
  • Boulder Hill Capital Management's Adaptimmune Therapeutics position peaked at $143K in Q1 2024.
  • 76 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2024.

Based on Boulder Hill Capital Management's 13F filing for Q2 2024.